English  |  正體中文  |  简体中文  |  Items with full text/Total items : 1657/1756
Visitors : 3727967      Online Users : 145
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister

Please use this identifier to cite or link to this item: http://140.112.115.32:8080/ir/handle/987654321/2787

Title: A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI
Authors: Shih, Tzenge-Lien;Lin, Kuan-Hung;Chen, Ray-Jade;Chen, Ting-Yu;Kao, Wei-Ting;Liu, Jen-Wei;Wang, Hsueh-Hsiao;Peng, Hsien-Yu;Sun, Yu-Yo;Lu, Wan-Jung
Contributors: 視光學系
Date: 2021-10-01
Issue Date: 2025-08-11 14:43:50 (UTC+8)
Abstract: Naphthalimide derivatives have multiple biological activities, including antitumour and anti-inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5–10 μM) inhibited collagen- and convulxin- but not thrombin- or U46619-mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more potent and efficient antiplatelet agents while minimizing bleeding risk, which may offer a therapeutic potential for cardiovascular diseases.
Relation: Journal of Cellular and Molecular Medicine, 25(19), 9434-9446. https://doi.org/https://doi.org/10.1111/jcmm.16886
Appears in Collections:[視光學系] 期刊論文

Files in This Item:

File SizeFormat
index.html0KbHTML1View/Open


All items in MMUIR are protected by copyright, with all rights reserved.

 


DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback